DSGN Design Corp: Price-to-Projected Revenue Ratio
The forward P/S ratio reflects the current valuation of Design Therapeutics (DSGN), where the parameter reaches . This trend is driven by the revision of clinical programs and the launch of new safety tests. The innovative GeneTAC platform for gene expression correction supports the increase in value. However, the lack of profitability and reliance on secondary offerings create significant risks due to the scientific uncertainty of the projects.
DSGN (Design Corp): analytical breakdowns and indicator data
- current price and projected stock value:
- company stock capitalization data:
- book value of equity indicators:
- debt and solvency information:
Total Debt to Capital Design Therapeutics|DSGN - Long-Term Liabilities to Capital|Short-Term Debt to Equity Ratio Design Therapeutics|DSGN - Company Aggregate Debts|Debt to Book Value Design Corp|DSGN - Amount of Long-Term Liabilities|Company Short-Term Debts Design Therapeutics|Quick Ratio designtx.com
- financial results and valuation multiples details:
DSGN - Net Income|Expected Profit Design Therapeutics|DSGN - Business Payback Period|Forward P/E Multiple Design Pharma|DSGN - Growth-Adjusted P/E Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Design Corp|DSGN - Operating income before deduction of amortization|Net earnings per share (EPS TTM) Design Therapeutics|DSGN - Net earnings per share for the trailing year|Year-over-year earnings per share growth for the last twelve months designtx.com|DSGN - Earnings per share growth this year|Earnings growth forecast for next year Design Therapeutics
- total revenue and sales volume data:
Fundamental company analysis:Design Therapeutics, Inc. (DSGN)
Professional selection of sustainable assets requires an analysis of the expected business value relative to its future cash flows. By evaluating the forward revenue multiple as the ratio of market capitalization to expected sales, an investor determines the premium paid for the potential of Design Therapeutics (DSGN), taking into account the costs of strict compliance with ethical and environmental standards in DNA therapy.
Competing companies
Forward P/S Multiple TEM (Tempus AI, Inc.)|Qiagen NV (QGEN) - Market Cap to Future Revenue Ratio|IONS - Price-to-Projected Revenue Ratio|Forward Price to Sales RGEN (Repligen Inc.)|RNA: Forward P/S Multiple|crisprtx.com (CRSP) - Forward P/S Multiple|Price-to-Projected Revenue Ratio GeneDx|Ultragenyx Pharmaceutical Inc. - Future Price to Revenue|Forward P/S Multiple BEAM|SRPT - Market Cap to Future Revenue Ratio|Twist Bioscience - Forward Price-to-Revenue Multiple|Forward P/S Multiple 10xgenomics.com TXG|NTLA: Forward Price-to-Revenue Multiple|Stoke Therapeutics Inc - Price to Expected Revenue Ratio|BLFS: Forward P/S Multiple|WVE - Market Cap to Expected Sales Ratio|MAZE (Maze Therapeutics Inc) - Forward P/S Multiple|Forward Price-to-Revenue Multiple sionnatx.com (SION)|Price-to-Projected Revenue Ratio Prime Medicine (PRME)|Market Cap to Expected Sales Ratio Taysha Gene Therapies Inc|Forward P/S Multiple QURE (uniQure Corp)|MGTX: Market Cap to Projected Revenue|RGNX - Price-to-Projected Revenue Ratio|Market Cap to Expected Sales Ratio solidbio.com SLDB|OCGN: Forward P/S Multiple|Projected Price to Revenue Pacific Biosciences of California, Inc. PACB|Price-to-Projected Revenue Ratio Benitec|Market Cap to Projected Revenue RCKT (Rocket Corp)|Forward P/S Multiple FDMT|lexeotx.com - Market Cap to Projected Revenue|Price-to-Projected Revenue Ratio Korro Bio KRRO|EDIT: Market Cap to Projected Revenue|Silence Therapeutics Inc. - Forward P/S Multiple|PRQR - Forward P/S Multiple|CDXS: Forward P/S Multiple|Market Cap to Projected Revenue SGMO|NAUT (Nautilus Biotechnology, Inc.) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Metagenomi Inc. MGX|Price-to-Projected Revenue Ratio Precision BioSciences, Inc. (DTIL)|Market Cap to Expected Sales Ratio generationbio.com|Forward P/S Multiple BOLD (Boundless Bio, Inc.)|Market Cap to Expected Sales Ratio Exicure Inc. (XCUR)|Celsion Corporation - Forward P/S Multiple|Projected Price to Revenue Phio Pharmaceuticals (PHIO)|mustangbio.com (MBIO) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue RNAZ|Forward Price-to-Revenue Multiple BNGO|APDN: Forward Price to Sales|Forward Price-to-Revenue Multiple BLUE (bluebird bio)|Price to Expected Revenue Ratio IPA|Forward P/S Multiple OMGA (Omega)|Forward Price to Sales OMIC|Regulus Therapeutics - Forward P/S Multiple|Market Cap to Future Revenue Ratio syros.com|Telesis Bio (TBIO) - Price-to-Projected Revenue Ratio|TRACON Pharmaceuticals Inc. - Forward Price to Sales|UBX (Unity Bio) - Forward P/S Multiple
